Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M E Hadley

Showing results (111-120 of 146) with videos related to

Pageof 15
Sort By:
The Journal of Investigative Dermatology|April 1, 1990
In vitro transdermal delivery of a melanotropic peptide through human skinB V Dawson, M E Hadley, N Levine, et al.
Journal of Medicinal Chemistry|August 15, 1997
beta-Methylation of the Phe7 and Trp9 melanotropin side chain pharmacophores affects ligand-receptor interactions and prolonged biological activityC Haskell-Luevano, K Toth, L Boteju, et al.
Journal of Medicinal Chemistry|May 12, 1995
Design, synthesis, biology, and conformations of bicyclic alpha-melanotropin analoguesC Haskell-Luevano, M D Shenderovich, S D Sharma, et al.
Peptides|January 1, 1994
Discovery of an alpha-melanotropin antagonist effective in vivoA M Castrucci, W C Sherbrooke, T K Sawyer, et al.
Pigment Cell Research|December 1, 1995
The melanotropic peptide, [Nle4,D-Phe7] alpha-MSH, stimulates human melanoma tyrosinase activity and inhibits cell proliferationJ Jiang, S D Sharma, S Nakamura, et al.
In Vitro Cellular & Developmental Biology : Journal of the Tissue Culture Association|February 1, 1986
Long-term and residual melanotropin-stimulated tyrosinase activity in S91 melanoma cells is density dependentZ A Abdel Malek, K L Kreutzfeld, M E Hadley, et al.
Cancer Research|October 1, 1985
Prolonged stimulation of S91 melanoma tyrosinase by [Nle4, D-Phe7]-substituted alpha-melanotropinsZ A Abdel Malek, K L Kreutzfeld, M M Marwan, et al.
Life Sciences|January 1, 1988
Transdermal delivery of a melanotropic peptide hormone analogueB V Dawson, M E Hadley, K Kreutzfeld, et al.
Life Sciences|March 23, 1987
Differential structural requirements for the MSH and MCH activities of melanin concentrating hormoneM E Hadley, C Zechel, B C Wilkes, et al.
Biopharmaceutics & Drug Disposition|April 1, 1997
Skin pigmentation and pharmacokinetics of melanotan-I in humansS O Ugwu, J Blanchard, R T Dorr, et al.
Pageof 15

Showing results (111-120 of 146) with videos related to

Sort By:
Pageof 15
The Journal of Investigative Dermatology|April 1, 1990
In vitro transdermal delivery of a melanotropic peptide through human skinB V Dawson, M E Hadley, N Levine, et al.
Journal of Medicinal Chemistry|August 15, 1997
beta-Methylation of the Phe7 and Trp9 melanotropin side chain pharmacophores affects ligand-receptor interactions and prolonged biological activityC Haskell-Luevano, K Toth, L Boteju, et al.
Journal of Medicinal Chemistry|May 12, 1995
Design, synthesis, biology, and conformations of bicyclic alpha-melanotropin analoguesC Haskell-Luevano, M D Shenderovich, S D Sharma, et al.
Peptides|January 1, 1994
Discovery of an alpha-melanotropin antagonist effective in vivoA M Castrucci, W C Sherbrooke, T K Sawyer, et al.
Pigment Cell Research|December 1, 1995
The melanotropic peptide, [Nle4,D-Phe7] alpha-MSH, stimulates human melanoma tyrosinase activity and inhibits cell proliferationJ Jiang, S D Sharma, S Nakamura, et al.
In Vitro Cellular & Developmental Biology : Journal of the Tissue Culture Association|February 1, 1986
Long-term and residual melanotropin-stimulated tyrosinase activity in S91 melanoma cells is density dependentZ A Abdel Malek, K L Kreutzfeld, M E Hadley, et al.
Cancer Research|October 1, 1985
Prolonged stimulation of S91 melanoma tyrosinase by [Nle4, D-Phe7]-substituted alpha-melanotropinsZ A Abdel Malek, K L Kreutzfeld, M M Marwan, et al.
Life Sciences|January 1, 1988
Transdermal delivery of a melanotropic peptide hormone analogueB V Dawson, M E Hadley, K Kreutzfeld, et al.
Life Sciences|March 23, 1987
Differential structural requirements for the MSH and MCH activities of melanin concentrating hormoneM E Hadley, C Zechel, B C Wilkes, et al.
Biopharmaceutics & Drug Disposition|April 1, 1997
Skin pigmentation and pharmacokinetics of melanotan-I in humansS O Ugwu, J Blanchard, R T Dorr, et al.
Pageof 15